Anke-Peggy is the founder of the Health Outcomes Strategies. Her areas of expertise are value of healthcare products and policy decisions on healthcare products for the in- and off-patent sector, reimbursement strategies, outcomes research and health economics, health technology assessment processes, payer interactions, product / device / service synergies, as well as patient involvement and engagement throughout Market Access / Patient Access activities.
Anke-Peggy has served as visiting faculty at the University of Utah between 2006 and 2007 and remains adjunct faculty in the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy, where she in addition to her academic contributions participated as investigator in a variety of outcomes studies. In addition, she has been invited repeatedly to teach a graduate course at the China Pharmaceutical University in Nanjing, China.
Anke-Peggy has published broadly, among others on subjects of Market access and health policy, evidence based decision making and quality assurance in healthcare. As member of the Health Technology Assessment international Association (HTAi) and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) she is engaged in the workgroups for Patient and Citizen Involvement in HTA (currently project coordinator), for Precision Medicines Methods and for Health Technology Assessment for pharmaceuticals, medical devices and diagnostics. Anke-Peggy has also been appointed as evaluator at the EU-commission on multiple occasions including SME funding programs and serves on the permanent accreditation boards for university programs in Germany.
Anke-Peggy obtained her PhD in natural sciences (Dr.rer.nat) from the University of Marburg (Germany) and her MBA from the University of Birmingham (United Kingdom), and she is certified for work in governing councils/administrative boards (Switzerland). She looks back on over 25 years of experience in the pharmaceutical and chemical industry in research and marketing with global responsibilities. Among others, she was responsible for the global Disease Management strategy and activities of Novartis Pharma, AG. Between 2000 and 2004, Dr. Holtorf managed the biotech business unit of a midsized Swiss chemical company and held a seat in the executive committee. Previously, she was responsible for technical development and quality assurance in the field of biologics produced in mammalian cell culture by the pharmaceutical industry.